Ping An Biomedical Co., Ltd.
PASW Nasdaq· Apparel & Other Finishd Prods Of Fabrics & Similar Matl
KIRA · Stoqly’s AI analyst, in plain words
- Ping An Biomedical Co., Ltd. had $4.7M of revenue in fiscal 2025, down 61.1% on the year before.
- Its operating margin was −43.1%, down 43.0 pts: of every 100 in sales, about −43 is left after running the business.
- Ping An Biomedical Co., Ltd. lost $1.8M in fiscal 2025.
- Ping An Biomedical Co., Ltd. owes $1.2M more than it holds in cash.
Market cap
—
P/E
—
Revenue
$4.7M
Net income
−$1.8M
Free cash flow
—
Operating margin
−43.1%
Ping An Biomedical Co., Ltd. in 30 seconds · fiscal 2025
Are sales growing?
−61.1%
No. Sales fell 61.1% last year.
Does it make a profit?
−37.6%
No. It lost money last year.
How healthy are the accounts?
3 / 9
Weak. It passes 3 of 9 health tests.
What Ping An Biomedical Co., Ltd. does
No business description yet.
- Fiscal year ends
- September 30, 2025
- Latest annual report
- 20-F · Jan 30, 2026
- Legal name
- Ping An Biomedical Co., Ltd.
- CIK
- 0001897532
Ping An Biomedical Co., Ltd. · PASW
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Revenue | $11.7M | $12.2M | $4.7M |
| Revenue growth | — | 3.9% | −61.1% |
| Gross margin | 5.1% | 6.2% | 2.8% |
| Operating margin | 0.7% | −0.0% | −43.1% |
| Net income | −$0.1M | −$0.2M | −$1.8M |
| Net margin | −1.2% | −1.5% | −37.6% |
| Diluted EPS | −$0.01 | −$0.01 | −$0.10 |
| Cash | |||
| Cash from operations | −$0.9M | $2.0M | −$0.9M |
| Dividends paid | $1.4M | $0.0M | — |
| Share count change | — | 0.0% | 2.7% |
| Debt and strength | |||
| Cash and short-term investments | $0.1M | $0.0M | $0.2M |
| Debt incl. finance leases | — | $1.4M | $1.4M |
| Shareholders' equity | −$0.8M | −$1.0M | $6.4M |
| Net debt / EBITDA | — | 1,279.4x | — |
| Current ratio | — | 0.8x | 2.8x |
| Interest coverage | 0.4x | −0.0x | −47.8x |
| Returns and quality | |||
| Return on capital | — | −0.1% | −21.2% |
| Return on equity | — | — | −66.7% |
| Return on tangible equity | — | — | −28.0% |
| Piotroski F-score | — | — | 3 |
| Altman Z'' | — | −1.8 | 3.5 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Ping An Biomedical Co., Ltd. · PASW
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Source: SEC EDGAR XBRL filings (CIK 0001897532). Data updated October 24, 2026. Filed in CNY under US GAAP and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.